BrainCool AB can today announce that two orders worth approximately 635 kUSD regarding consumables for the US market have been received from the company's distribution partner ZOLL®. The first order (317 kUSD) will start to be delivered from the end of March and the second order (318 kUSD) is within the framework of the Zoll agreement, which was communicated in connection with the conclusion of the agreement with Zoll®.
 
 Martin Waleij, Head of Commercial Operations comments:
“Implementation of the IQOOL™ System product in the US has exceeded expectations. We are now seeing an increasing utilization rate of the products on the market and the products are attracting great interest from new potential customers. As the production rate increases, we will further accelerate market activities”.
 
Jon Berg, CEO comments:
“We have a close collaboration with our supplier TM Rubber in Poland for consumables where we are now redesigning the manufacturing method itself and automating the process. This means that we double the capacity already in the second quarter and multiply it further in the second half of the year when the investment in 'injection moulding' is implemented.”
 

Contact
For more information
Jon Berg - CEO
+46 722 50 91 19
e-mail: jon.berg@braincool.se

About Us
BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named “BRAIN”.
Eminova Fondkommission AB is the company’s Certified Adviser.

This information is information that BrainCool is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-27 11:56 CET.

Attachments
BrainCool AB (publ): receives orders for consumables for the US market of SEK 6.5 million